BioTime, Inc. Press Releases

BTX 
$3.25
*  
0.11
3.27%
Get BTX Alerts
*Delayed - data as of Oct. 22, 2014  -  Find a broker to begin trading BTX now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury
10/20/2014 6:30:00 AM - PR Newswire


BioTime, Inc. Closes $31 Million Financing
10/9/2014 9:00:00 AM - Business Wire
▼-2.11 % Price Change since this news event. The Volume Ratio is 0.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Asterias Biotherapeutics to List its Series A Common Stock on NYSE MKT
10/6/2014 4:16:00 PM - PR Newswire


Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
10/6/2014 8:30:00 AM - Business Wire


BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen® Designed to Treat Patients with Dry-AMD
10/6/2014 8:00:00 AM - Business Wire


BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares
10/6/2014 7:00:00 AM - Business Wire


BioTime’s Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute
10/3/2014 9:00:00 AM - Business Wire


LifeMap Solutions Adds Chief Technology Officer to Leadership Team
10/1/2014 9:00:00 AM - Business Wire


Asterias Biotherapeutics Announces Distribution Date of BioTime Warrants and Conversion Date of Series B Common Stock into Series A Common Stock
9/29/2014 9:13:00 AM - Business Wire


BioTime, Inc.’s Subsidiary OncoCyte Corporation’s CEO Dr. Joseph Wagner to Present at BTIG’s Inaugural “Emerging Technologies in Healthcare Diagnostics” Symposium
9/19/2014 9:00:00 AM - Business Wire


BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen® in Preclinical Animal Studies
9/17/2014 9:00:00 AM - Business Wire


BioTime, Inc.’s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development
9/15/2014 9:00:00 AM - Business Wire


BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer
9/11/2014 4:14:00 PM - Business Wire


Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer
9/11/2014 6:00:00 AM - PR Newswire


BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference
9/9/2014 9:00:00 AM - Business Wire


Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock
9/4/2014 4:01:00 PM - PR Newswire


BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem®-Based Hydrogel for Vocal Fold Scarring
8/28/2014 9:00:00 AM - Business Wire


BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury
8/27/2014 9:00:00 AM - Business Wire


Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
8/27/2014 6:00:00 AM - PR Newswire


Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
8/25/2014 7:00:00 AM - PR Newswire


Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
8/21/2014 7:00:00 AM - PR Newswire


BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)
8/12/2014 9:00:00 AM - Business Wire


BioTime Announces Second Quarter 2014 Results and Recent Developments
8/12/2014 8:00:00 AM - Business Wire


Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire


BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial
7/31/2014 9:00:00 AM - Business Wire


    • << first
    • < previous
    • 1
    • next >
    • last >>